| Drug Transport and Resistance Mechanisms | Lifetime | 23 | US 14 | 99.75 |
| Cancer therapeutics and mechanisms | Lifetime | 53 | US 33 | 99.54 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 174 | US 73 | 98.91 |
| HIV/AIDS drug development and treatment | Lifetime | 240 | US 131 | 99.08 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 608 | US 178 | 97.70 |
| Cancer Mechanisms and Therapy | Lifetime | 329 | US 152 | 96.60 |
| Trace Elements in Health | Lifetime | 584 | US 236 | 96.86 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 860 | US 372 | 96.49 |
| Pregnancy and Medication Impact | Lifetime | 838 | US 327 | 92.80 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 2 | US 1 | 99.83 |
| Cancer therapeutics and mechanisms | 2021-2025 | 5 | US 3 | 99.45 |
| Epigenetics and DNA Methylation | 2021-2025 | 71 | US 26 | 98.28 |
| HIV/AIDS drug development and treatment | 2021-2025 | 36 | US 14 | 97.96 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 41 | US 24 | 96.67 |
| MicroRNA in disease regulation | 2021-2025 | 180 | US 12 | 97.57 |
| RNA modifications and cancer | 2021-2025 | 375 | US 66 | 96.71 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 164 | US 46 | 95.42 |
| Cancer-related gene regulation | 2021-2025 | 98 | US 23 | 94.24 |
| Cancer Mechanisms and Therapy | 2021-2025 | 75 | US 14 | 94.31 |
| Cancer-related Molecular Pathways | 2021-2025 | 125 | US 57 | 92.72 |
| Immunotherapy and Immune Responses | 2021-2025 | 775 | US 249 | 92.09 |
| Nanoparticle-Based Drug Delivery | 2021-2025 | 424 | US 20 | 93.62 |
| Ferroptosis and cancer prognosis | 2021-2025 | 696 | US 56 | 91.87 |
| Microtubule and mitosis dynamics | 2021-2025 | 115 | US 49 | 90.32 |
| Protein Degradation and Inhibitors | 2021-2025 | 448 | US 203 | 91.44 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 791 | US 151 | 85.55 |
| Circular RNAs in diseases | 2021-2025 | 818 | US 47 | 86.99 |
| Ubiquitin and proteasome pathways | 2021-2025 | 700 | US 178 | 84.37 |
| PARP inhibition in cancer therapy | 2021-2025 | 549 | US 204 | 85.77 |
| Cancer Research and Treatments | 2021-2025 | 582 | US 162 | 83.07 |
| Advanced Breast Cancer Therapies | 2021-2025 | 729 | US 257 | 86.75 |
| Click Chemistry and Applications | 2021-2025 | 545 | US 56 | 85.22 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 146 | US 36 | 82.08 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 879 | US 325 | 85.34 |
| Cancer Treatment and Pharmacology | 2021-2025 | 897 | US 292 | 84.57 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 603 | US 160 | 83.52 |
| Phagocytosis and Immune Regulation | 2021-2025 | 494 | US 138 | 74.27 |
| Cell death mechanisms and regulation | 2021-2025 | 262 | US 49 | 70.00 |
| Biochemical and Molecular Research | 2021-2025 | 574 | US 122 | 69.97 |
| Neonatal Health and Biochemistry | 2021-2025 | 856 | US 224 | 63.59 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 921 | US 311 | 60.43 |
| FOXO transcription factor regulation | 2021-2025 | 318 | US 82 | 47.01 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 638 | US 109 | 29.49 |
